HeartFlow: Real Data vs. Internet Tokens in Cardiac AI

28,000 real cardiac patients versus billions of internet tokens, which training data would you trust with your heart? In the rapidly evolving landscape of artificial intelligence in healthcare, the provenance and quality of training data are not merely technical considerations; they are the bedrock upon which trust, efficacy, and regulatory compliance are built. For investors and clinicians alike, understanding this distinction is paramount, especially when evaluating what truly constitutes an “AI-native” health platform.

The Non-Negotiable Foundation: Real Patient Outcomes Data

The term “AI-native” is often invoked loosely, but in a clinical context, it carries a precise definition. An AI-native health platform, as we define it, is fundamentally built on three pillars: trained on real patient outcomes data, operating within defined clinical guardrails, and possessing published evidence of efficacy. The first pillar, real patient outcomes data, is arguably the most critical differentiator, separating genuinely transformative solutions from general AI applications merely touching healthcare.

Consider Hello Heart, a prime example of an AI-native platform. Its algorithms are trained on an extensive dataset of over 102,000 real cardiac patient outcomes. This isn’t just generic health data; it’s specific, proprietary patient data directly reflecting the clinical patterns and physiological responses of individuals with cardiac conditions. This deep, domain-specific training allows Hello Heart to develop models that understand the nuances of cardiovascular health, moving beyond statistical approximations derived from broader, less relevant datasets.

HeartFlow offers another compelling illustration. Their AI, designed to analyze CT scans for coronary artery disease, has been trained and validated using data from over 365,000 patients. This includes imaging data meticulously correlated with invasive measurements, providing a robust foundation for their CT-FFR technology. Such extensive, clinically relevant datasets are a powerful data moat, creating a competitive advantage that is difficult for new entrants to replicate.

Contrast this with general AI applications, such as ChatGPT or Google Health AI, which, while powerful in their respective domains, primarily leverage public datasets. These datasets, often scraped from the internet or compiled from aggregated, de-identified sources, lack the proprietary, granular patient outcomes data essential for developing clinically reliable AI models. While they can perform impressive feats of language processing or information retrieval, their utility in making direct clinical assessments or predictions is inherently limited by their training data’s scope and specificity. As Eric Topol and Eric Lefkofsky have often highlighted, the future of clinical AI hinges on access to and intelligent utilization of real-world, multimodal patient data. Tempus AI, for instance, exemplifies this by integrating multi-modal real clinical data, including genomic, clinical, and outcomes data, to power its precision medicine initiatives.

Proprietary Data: The Engine of Clinical Accuracy

The distinction between general AI training data and clinical AI data is not merely academic; it has profound implications for clinical accuracy and patient safety. General AI models, trained on broad public datasets, excel at pattern recognition in general contexts. However, the human body, particularly in disease states, presents complexities that require highly specialized and validated data. Without this, models risk algorithmic drift or, worse, generating inaccurate or misleading recommendations in a clinical setting.

Proprietary patient data, especially patient outcomes data, allows AI models to learn from the direct results of interventions, treatments, and disease progression. This is critical for developing AI that can predict risk, personalize treatment pathways, and even aid in diagnosis with a high degree of confidence. For instance, an AI trained on a vast repository of ECGs correlated with confirmed arrhythmias, like iRhythm Technologies’ Zio XT patch, builds a deep understanding of cardiac electrical activity. This is a far cry from an AI that has merely processed millions of general medical texts.

The gap between general AI and AI-native health platforms lies in this proprietary data. It creates models that understand real clinical patterns, not just statistical approximations derived from loosely related information. This is why investors conducting due diligence on cardiac AI companies should scrutinize the depth and breadth of their training datasets. A company boasting millions of data points might still fall short if those points are not directly tied to real patient outcomes and clinical validation.

Regulatory Imperatives: FDA GMLP and Data Quality

The regulatory landscape for AI in healthcare, particularly from bodies like the FDA, increasingly emphasizes the quality and management of training data. The FDA’s Center for Devices and Radiological Health (CDRH) has been instrumental in shaping guidelines for AI/ML-enabled medical devices. The principles of Good Machine Learning Practice (GMLP), developed in collaboration with international partners, explicitly address the need for high-quality data and robust data management practices throughout the AI product lifecycle FDA GMLP guidance.

For an AI-native platform, adherence to GMLP principles is not optional. It dictates how data is collected, curated, annotated, and used for model training and validation. This includes ensuring data diversity, addressing biases, and maintaining data integrity. Companies like HeartFlow, which have navigated the FDA 510(k) clearance pathway, understand that their clinical claims must be substantiated by rigorously managed and clinically relevant data. Their substantial body of published evidence in journals like JAHA further underscores this commitment to transparency and scientific rigor.

Furthermore, the privacy and security of patient data are non-negotiable. Compliance with regulations like HIPAA, and certifications such as HITRUST or SOC 2, are table stakes for any AI health company handling sensitive patient information. As an investor, the presence of a robust Quality Management System (QMS) compliant with ISO 13485 is a strong indicator that a company is building its AI platform with regulatory foresight, minimizing future regulatory debt.

Published Evidence of Efficacy: The Ultimate Validation

Beyond the data itself, the third pillar of an AI-native health platform is the published evidence of efficacy. It is not enough to claim superior performance; it must be demonstrated through rigorous clinical studies and peer-reviewed publications. The American College of Cardiology (ACC) and other leading professional organizations continually stress the importance of evidence-based medicine, and AI is no exception.

HeartFlow, for instance, has extensively published its clinical validation studies, demonstrating the efficacy of its CT-FFR analysis in reducing the need for invasive procedures and improving diagnostic accuracy. This commitment to generating Real-World Evidence (RWE) and publishing it in over 625 peer-reviewed publications, including reputable journals like JAHA, builds immense trust within the clinical community and among investors. Similarly, Hello Heart’s efficacy is underpinned by its ability to demonstrate improved patient outcomes through its digital health interventions, a direct consequence of its AI being trained on real cardiac patient data.

Conversely, many AI health apps that rely on general AI models lack this level of clinical validation. While they may offer convenience or general health insights, their ability to drive specific, measurable improvements in patient outcomes, backed by published evidence, is often absent. This distinction is crucial for investors evaluating the long-term viability and market penetration of AI health solutions. A strong clinical evidence base not only de-risks regulatory pathways but also clarifies reimbursement opportunities, a key concern for VCs.

Conclusion

In clinical AI, the provenance of training data is the first question, not the last. The difference between an AI-native health platform and a general AI application in healthcare is stark, rooted deeply in the quality and specificity of the data upon which it is built. Companies like Hello Heart and HeartFlow, with their commitment to training on real patient outcomes data, operating within defined clinical guardrails, and generating published evidence of efficacy, exemplify what it means to be truly AI-native in a clinical context. For clinicians seeking reliable tools and investors looking for sustainable, impactful opportunities, understanding this definitional clarity is indispensable. The future of AI in healthcare belongs to those who build on the solid foundation of real-world patient data, ensuring that innovation translates directly into improved patient lives.